N-PORT filing recap · October 2023

What did ARK Genomic Revolution ETF buy in October 2023?

Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.

Stock value

$1.43B

Positions

Estimated turnover

9.6%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

Increased positions

PACBPacific Biosciences of California, Inc.$72.10Mreported value+367.2K shares+3.2%DNAGinkgo Bioworks Holdings, Inc.$71.26Mreported value+1.32M shares+2.6%CRSPCrispr Therapeutics AG$62.82Mreported value+74.1K shares+4.8%NTLAIntellia Therapeutics, Inc.$54.93Mreported value+261.3K shares+13.5%ADPTAdaptive Biotechnologies Corporation$50.08Mreported value+234.4K shares+2.1%BEAMBeam Therapeutics Inc.$49.80Mreported value+183.8K shares+8.5%RXRXRecursion Pharmaceuticals, Inc.$39.52Mreported value+2.43M shares+48.2%VERVVerve Therapeutics, Inc.$36.12Mreported value+30.7K shares+1.0%TXG10x Genomics, Inc.$28.64Mreported value+57.8K shares+7.7%MRNAModerna, Inc.$22.08Mreported value+42.7K shares+17.2%PRMEPrime Medicine, Inc.$17.55Mreported value+481.9K shares+21.7%NRIXNurix Therapeutics, Inc.$16.25Mreported value+572.4K shares+24.5%NVTAInvitae Corp$5.43Mreported value+215.4K shares+2.5%

Reduced positions

EXASExact Sciences Corporation$153.96Mreported value-161.7K shares-6.1%IONSIonis Pharmaceuticals, Inc.$90.84Mreported value-448.7K shares-17.9%TDOCTeladoc Health, Inc.$64.96Mreported value-124.1K shares-3.1%SDGRSchrodinger, Inc.$60.29Mreported value-729.1K shares

Exited positions

CDXSCodexis, Inc.$12.54Mprior reported value-3.48M shares-100.0%BLIUSDPhenomex Inc$1.26Mprior reported value-2.28M shares-100.0%IOVAIovance Biotherapeutics Inc$253.0Kprior reported value-34.9K shares-100.0%SURFSurface Oncology Inc$63prior reported value-65 shares